Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research on breast cancer detailed by J.L. Bayocalero and co-authors
August 7th, 2008
According to recent research published in the journal Clinical Breast Cancer, "Trastuzumab combined with cytotoxic agents presents encouraging results in metastatic breast cancer (MBC), but cardiac toxicity limits some combinations. The synergism shown with trastuzumab and the favorable tolerability profile of vinorelbine provided the rationale for investigating this combination." "Patients with HER2-positive MBC who had received < 2 lines of chemotherapy for metastatic disease were included. Vinorelbine (25 mg/m(2) on day 2, then weekly on day 1) and trastuzumab (4 mg/kg on day 1, then 2 mg/kg weekly) were administered for a maximum of 6 cycles (1 cycle = 3...
Source: Women's Health Weekly (2008-08-07)
|
